Nuvectis (NVCT) director buys 11,000 shares at $5.84 avg; holds 124,760

Nuvectis Pharma (NVCT): Director Matthew Kaplan purchased 11,000 shares of common stock on 11/05/2025 in an open‑market transaction coded “P” at a weighted average price of $5.84.

Rhea-AI Filing Summary

Nuvectis Pharma (NVCT): Director Matthew Kaplan purchased 11,000 shares of common stock on 11/05/2025 in an open‑market transaction coded “P” at a weighted average price of $5.84. Following this trade, he beneficially owns 124,760 shares, held directly.

The filing notes the price was a weighted average across multiple same‑day trades within a $5.81–$5.88 range, and detailed breakdowns are available upon request.

Insider Trade Summary

Net Buyer: 11,000 shares

Net Buy 1 txn

Insider Kaplan Matthew L.

Role Director

Bought 11,000 shs ($64K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	11,000	$5.84	$64K

Holdings After Transaction: Common Stock — 124,760 shares (Direct)

Footnotes (1)

1. F1. Reflects the weighted average purchase price. The range of prices for the shares purchased was $5.81 to $5.88. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NVCT disclose in this Form 4?

A director, Matthew Kaplan, purchased 11,000 NVCT shares on 11/05/2025 at a $5.84 weighted average price.

What is the director’s total NVCT ownership after the trade?

After the reported transaction, the director beneficially owns 124,760 shares, held directly.

What was the price range for the NVCT share purchases?

The purchases were executed within a $5.81–$5.88 price range on the same day.

How was the transaction coded on the Form 4?

The transaction was coded “P”, indicating an open‑market or private purchase of NVCT common stock.

Is there detail for each individual trade price?

Yes. The filing states detailed trade‑by‑trade prices are available upon request from the SEC staff, the issuer, or a shareholder.

Was the ownership reported as direct or indirect?

The Form 4 lists the ownership form as Direct (D).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/06/2025 - 08:00 AM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaplan Matthew L.

(Last) (First) (Middle)

C/O NUVECTIS PHARMA, INC.,

1 BRIDGE PLAZA, SUITE 275

(Street)

FORT LEE NJ 07024

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuvectis Pharma, Inc. [ NVCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/05/2025		P		11,000(1)	A	$5.84	124,760	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects the weighted average purchase price. The range of prices for the shares purchased was $5.81 to $5.88. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.

	/s/ Matthew Kaplan	11/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.